FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888157059> ?p ?o ?g. }

• W2888157059 endingPage "75" @default.
• W2888157059 startingPage "67" @default.
• W2888157059 abstract "BackgroundInterleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-powder formulation containing CDP7766, a high-affinity anti-human-IL-13 antigen-binding antibody fragment being developed for the treatment of asthma.MethodsWe conducted a phase 1, randomized, double-blind, placebo-controlled, ascending-dose study at Hammersmith Medicines Research, London, UK, which is now complete. Healthy adults aged 18–50 years (n = 40) were randomized 3:1 to a single inhaled dose of VR942 0.5, 1.0, 5.0, 10, or 20 mg, or placebo. Adults aged 18–50 years who were diagnosed with asthma for ≥6 months before screening, and had forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) values ≥70% of the predicted values at screening (n = 45), were randomized to once-daily inhaled VR942 0.5 or 10 mg, or placebo (2:2:1), or VR942 20 mg or placebo (3:2), for 10 days. All participants were randomized to receive VR942 or placebo based on a randomization list prepared by an independent HMR statistician using SAS® software ( SAS Institute , Cary, NC). The primary outcome was safety and tolerability of VR942 (safety population, defined as all who received at least one dose of VR942 or placebo). This study is listed on ClinicalTrials.gov (NCT02473939).FindingsIn the VR942 and placebo groups, treatment-emergent adverse events (TEAEs) were reported in 10/30 (33%) and 0/10 (0%) healthy participants, and in 16/29 (55%) and 9/16 (56%) participants with asthma, respectively. Mild intermittent wheezing occurred in 7 participants (VR942 20 mg, n = 4; corresponding placebo, n = 3), resolving spontaneously within 1 h. All TEAEs were mild or moderate; there were no deaths, serious adverse events, or clinically significant changes in vital signs, electrocardiograms, or laboratory parameters. There was no clinically significant immunogenicity, with only one participant with asthma considered positive for treatment-related immunogenicity for CDP7766.InterpretationThis study, considered to be the only example of a dry powder anti-IL-13 fragment antibody being administered via inhalation, demonstrated that single and repeat doses were well tolerated over a period of up to 10 days in duration. Rapid and durable inhibition of fractional exhaled nitric oxide (FeNO) (secondary outcome) provided evidence of pharmacological engagement with the IL-13 target in the airways of participants diagnosed with mild asthma. These data, together with the numerical improvements observed for predose FEV1, justify further clinical evaluation of VR942 in a broader population of patients with asthma, and continue to support the development of an inhaled anti-IL-13 antibody fragment as a potential future treatment that is alternative to monoclonal antibodies delivered via the parenteral route.FundingStudy funding and funding for the medical writing and editorial support for preparation of the manuscript were split equally between the two study co-funders (Vectura Ltd and UCB Pharma)." @default.
• W2888157059 created "2018-08-31" @default.
• W2888157059 creator A5024403034 @default.
• W2888157059 creator A5026324866 @default.
• W2888157059 creator A5027981077 @default.
• W2888157059 creator A5039845119 @default.
• W2888157059 creator A5042927556 @default.
• W2888157059 creator A5051290674 @default.
• W2888157059 creator A5054396764 @default.
• W2888157059 creator A5059941306 @default.
• W2888157059 creator A5070428279 @default.
• W2888157059 creator A5073975770 @default.
• W2888157059 creator A5080273590 @default.
• W2888157059 creator A5081577418 @default.
• W2888157059 date "2018-09-01" @default.
• W2888157059 modified "2023-10-14" @default.
• W2888157059 title "Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942" @default.
• W2888157059 cites W1549472286 @default.
• W2888157059 cites W1963614579 @default.
• W2888157059 cites W1989840930 @default.
• W2888157059 cites W1990965457 @default.
• W2888157059 cites W1991057609 @default.
• W2888157059 cites W2022877219 @default.
• W2888157059 cites W2036075099 @default.
• W2888157059 cites W2043943442 @default.
• W2888157059 cites W2046313062 @default.
• W2888157059 cites W2076210324 @default.
• W2888157059 cites W2107207387 @default.
• W2888157059 cites W2127482775 @default.
• W2888157059 cites W2128472414 @default.
• W2888157059 cites W2132403618 @default.
• W2888157059 cites W2141343329 @default.
• W2888157059 cites W2150849592 @default.
• W2888157059 cites W2153395214 @default.
• W2888157059 cites W2167829087 @default.
• W2888157059 cites W2168421693 @default.
• W2888157059 cites W2300879999 @default.
• W2888157059 cites W2342693354 @default.
• W2888157059 cites W2360510406 @default.
• W2888157059 cites W2480571942 @default.
• W2888157059 cites W2515900781 @default.
• W2888157059 cites W2803404900 @default.
• W2888157059 cites W2994597783 @default.
• W2888157059 cites W4211006694 @default.
• W2888157059 doi "https://doi.org/10.1016/j.ebiom.2018.07.035" @default.
• W2888157059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156733" @default.
• W2888157059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30146344" @default.
• W2888157059 hasPublicationYear "2018" @default.
• W2888157059 type Work @default.
• W2888157059 sameAs 2888157059 @default.
• W2888157059 citedByCount "42" @default.
• W2888157059 countsByYear W28881570592018 @default.
• W2888157059 countsByYear W28881570592019 @default.
• W2888157059 countsByYear W28881570592020 @default.
• W2888157059 countsByYear W28881570592021 @default.
• W2888157059 countsByYear W28881570592022 @default.
• W2888157059 countsByYear W28881570592023 @default.
• W2888157059 crossrefType "journal-article" @default.
• W2888157059 hasAuthorship W2888157059A5024403034 @default.
• W2888157059 hasAuthorship W2888157059A5026324866 @default.
• W2888157059 hasAuthorship W2888157059A5027981077 @default.
• W2888157059 hasAuthorship W2888157059A5039845119 @default.
• W2888157059 hasAuthorship W2888157059A5042927556 @default.
• W2888157059 hasAuthorship W2888157059A5051290674 @default.
• W2888157059 hasAuthorship W2888157059A5054396764 @default.
• W2888157059 hasAuthorship W2888157059A5059941306 @default.
• W2888157059 hasAuthorship W2888157059A5070428279 @default.
• W2888157059 hasAuthorship W2888157059A5073975770 @default.
• W2888157059 hasAuthorship W2888157059A5080273590 @default.
• W2888157059 hasAuthorship W2888157059A5081577418 @default.
• W2888157059 hasBestOaLocation W28881570591 @default.
• W2888157059 hasConcept C111113717 @default.
• W2888157059 hasConcept C112705442 @default.
• W2888157059 hasConcept C126322002 @default.
• W2888157059 hasConcept C142724271 @default.
• W2888157059 hasConcept C159654299 @default.
• W2888157059 hasConcept C168563851 @default.
• W2888157059 hasConcept C197934379 @default.
• W2888157059 hasConcept C203014093 @default.
• W2888157059 hasConcept C204243189 @default.
• W2888157059 hasConcept C204787440 @default.
• W2888157059 hasConcept C27081682 @default.
• W2888157059 hasConcept C2776042228 @default.
• W2888157059 hasConcept C2778375690 @default.
• W2888157059 hasConcept C2780868878 @default.
• W2888157059 hasConcept C2908647359 @default.
• W2888157059 hasConcept C71924100 @default.
• W2888157059 hasConcept C98274493 @default.
• W2888157059 hasConcept C99454951 @default.
• W2888157059 hasConceptScore W2888157059C111113717 @default.
• W2888157059 hasConceptScore W2888157059C112705442 @default.
• W2888157059 hasConceptScore W2888157059C126322002 @default.
• W2888157059 hasConceptScore W2888157059C142724271 @default.
• W2888157059 hasConceptScore W2888157059C159654299 @default.
• W2888157059 hasConceptScore W2888157059C168563851 @default.
• W2888157059 hasConceptScore W2888157059C197934379 @default.
• W2888157059 hasConceptScore W2888157059C203014093 @default.
• W2888157059 hasConceptScore W2888157059C204243189 @default.

• next